An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice
NCT ID: NCT01474291
Last Updated: 2016-10-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
608 participants
OBSERVATIONAL
2012-01-31
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tocilizumab
Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.
Tocilizumab
Tocilizumab administered according to prescribing information and normal clinical practice.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tocilizumab
Tocilizumab administered according to prescribing information and normal clinical practice.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with rheumatoid arthritis for whom the rheumatologist decides to start tocilizumab in combination with DMARD or as monotherapy
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aix-les-Bains, , France
Amiens, , France
Amiens, , France
Angers, , France
Auch, , France
Aulnay-sous-Bois, , France
Avignon, , France
Bastia, , France
Bayonne, , France
Beauvais, , France
Belfort, , France
Belley, , France
Berck, , France
Besançon, , France
Bobigny, , France
Bois-Guillaume, , France
Bondy, , France
Bonneville, , France
Bordeaux, , France
Bordeaux, , France
Boulogne-Billancourt, , France
Bressuire, , France
Brest, , France
Bry-sur-Marne, , France
Caen, , France
Cahors, , France
Cannes, , France
Carcassonne, , France
Chambray-lès-Tours, , France
Chambray-lès-Tours, , France
Châteauroux, , France
Clermont-Ferrand, , France
Colmar, , France
Compiègne, , France
Corbeil-essones, , France
Corbeil-Essonnes, , France
Créteil, , France
Denain, , France
Digne-les-Bains, , France
Dijon, , France
Dole, , France
Draguignan, , France
Druex, , France
Échirolles, , France
Épernay, , France
Évian-les-Bains, , France
Évreux, , France
Évry, , France
Freyming-Merlebach, , France
Fréjus, , France
Gap, , France
Gleizé, , France
Haguenau, , France
Ivry-sur-Seine, , France
Laon, , France
Lavaur, , France
Le Bouscat, , France
Le Coudray, , France
Le Kremlin-Bicêtre, , France
Libourne, , France
Liévin, , France
Lille, , France
Limoges, , France
Limoges, , France
Lomme, , France
Lyon, , France
Lyon, , France
Maisons-Laffitte, , France
Marseille, , France
Marseille, , France
Marseille, , France
Metz-Tessy, , France
Montauban, , France
Montpellier, , France
Moulins, , France
Mulhouse, , France
Nanterre, , France
Nantes, , France
Narbonne, , France
Nevers, , France
Nice, , France
Nîmes, , France
Orange, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Perpignan, , France
Périgueux, , France
Pierre-Bénite, , France
Poissy, , France
Pontoise, , France
Reims, , France
Rennes, , France
Rodez, , France
Roubaix, , France
Saint-Brieuc, , France
Saint-Chamond, , France
Saint-Mandé, , France
Saint-Priest-en-Jarez, , France
Salon-de-Provence, , France
Ste Maxime, , France
Strasbourg, , France
Suresnes, , France
Thionville, , France
Toulon, , France
Toulouse, , France
Toulouse, , France
Toulouse, , France
Tourcoing, , France
Valenciennes, , France
Valenciennes, , France
Vandœuvre-lès-Nancy, , France
Vannes, , France
Villeneuve-Saint-Georges, , France
Villeurbanne, , France
Vlleneuve Sur Lot, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Flipo RM, Maillefert JF, Chazerain P, Idier I, Coudert M, Tebib J. Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study. RMD Open. 2017 Jan 10;3(1):e000340. doi: 10.1136/rmdopen-2016-000340. eCollection 2017.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML27873
Identifier Type: -
Identifier Source: org_study_id